Comprehensive Analysis of Immune Implications and Prognostic Value of SPI1 in Gastric Cancer
Open accessAbstract
Background: The transcription factor Spi-1 proto-oncogene (SPI1, also known as PU.1) is a key regulator of signal communication in the immune system and is essential for the development of myeloid cells and lymphocytes. However, the potential role of SPI1 in gastric cancer (GC) and the correlations between SPI1 and immune infiltration remain unclear. Methods: In the present study, multiple databases including ONCOMINE, TIMER, Kaplan–Meier Plotter, and The Cancer Genome Atlas were used to explore the expression levels and prognostic value of SPI1 in GC. cBioPortal was used to explore the possible reasons for the increased expression of SPI1 in GC. The correlations between SPI1 expression and tumor-infiltrating immune cells (TICs) were analyzed using CIBERSORT and TIMER. Gene set enrichment analysis was used to determine the biological function of SPI1 in the development of GC. In addition, a risk signature based on SPI1-related immunomodulators was constructed to accurately evaluate the prognosis of patients with GC. The upregulation of SPI1 expression in GC was further confirmed through immunohistochemistry, western blotting, and real-time quantitative PCR (RT-qPCR) assay. Results: The expression of SPI1 was increased significantly in GC according to multiple databases, and high expression of SPI1 was related to poor prognosis and progression of GC. The main factor influencing the high expression of SPI1 mRNA in GC may be diploidy, not DNA methylation. Moreover, immunohistochemistry, western blotting, and RT-qPCR assays also confirmed the upregulated expression of SPI1 in GC. CIBERSORT analysis revealed that SPI1 expression was correlated with seven types of TICs (naive B cells, resting memory CD4 T cells, activated memory CD4 T cells, activated natural killer cells, resting natural killer cells, M2 macrophages, and resting dendritic cells). Gene set enrichment analysis indicated that SPI1 might be related to immune activation in GC and participate in cell cycle regulation. In addition, based on SPI1-related immunomodulators, we developed multiple-gene risk prediction signatures and constructed a nomogram that can independently predict the clinical outcome of GC. Conclusion: The results of the present study suggest that SPI1 has a critical role in determining the prognosis of GC patients and may be a potential immunotherapeutic target.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SPI1 is essential for the differentiation and function of lymphoid and myeloid cells.
“the transcription factor SPI1—essential for the differentiation and function of lymphoid and myeloid cells [25]—has also been implicated in inflammatory regulation.”
From Inhibition of SPI1 by ADAP Regulates S100A8/A9 Signaling in Macrophages to Control the Development of Colitis (2026) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Yu, S., Hu, C., Cai, L., Du, X., Lin, F. Y., Yu, Q., Liu, L., Zhang, C. L., Liu, X., Li, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01778 · Cited by 64 · see citing works
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · see citing works
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N. C., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,914 · see citing works
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,208 · see citing works
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. T., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,876 · see citing works
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836 · see citing works
TISIDB: an integrated repository portal for tumor–immune system interactions
Ru, B., Wong, C. N., Tong, Y., Zhong, J. Y., Zhong, S. S. W., Wu, W. C., Chu, K. C., Wong, C. Y., Lau, C. Y., Chen, I., et al. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz210 · Cited by 2,388 · see citing works
Rhodes, D. R., Sundaram, S. K., Mahavisno, V., Varambally, R., Yu, J., Briggs, B., Barrette, T. R., Anstett, M. J., Kincead-Beal, C., Kulkarni, P., et al. (2007) · Neoplasia · doi:10.1593/neo.07112 · Cited by 2,051 · see citing works
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130 · see citing works
Zhang, Q., Liu, L., Gong, C., Shi, H., Zeng, Y., Wang, X., Zhao, Y., & Wei, Y.-Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050946 · Cited by 1,041 · see citing works
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863 · see citing works
Lánczky, A., Nagy, Á. M., Bottai, G., Munkácsy, G., Szabó, A., Santarpia, L., & Győrffy, B. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4013-7 · Cited by 769 · see citing works
M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer
Lan, J., Sun, L., Xu, F., Liu, L., Hu, F., Song, D., Hou, Z., Wu, W., Luo, X., Wang, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0014 · Cited by 643 · see citing works
Chen, Y., Zhang, S., Wang, Q., & Zhang, X. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0408-0 · Cited by 481 · see citing works
Spi-1 is a putative oncogene in virally induced murine erythroleukaemias
Moreau-Gachelin, F., Tavitian, A., & Tambourin, P. (1988) · Nature · doi:10.1038/331277a0 · Cited by 447 · see citing works
A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease
The International Genomics of Alzheimer's Project, Huang, K.-L., Initiative, T. A. D. N., Marcora, E., Pimenova, A. A., Di Narzo, A. F., Kapoor, M., Jin, S. C., Harari, O., Bertelsen, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4587 · Cited by 423 · see citing works
A new pattern for helix–turn–helix recognition revealed by the PU.l ETS–domain–DNA complex
Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R. A., & Ely, K. R. (1996) · Nature · doi:10.1038/380456a0 · Cited by 315 · see citing works
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
Lee, H. E., Chae, S. W., Lee, Y. J., Kim, M., Lee, H. S., Lee, B. L., & Kim, W. H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604738 · Cited by 302 · see citing works
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 292 · see citing works
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity
Büll, C., Boltje, T. J., Balneger, N., Weischer, S., Wassink, M., van Gemst, J. J., Bloemendal, V. R. L. J., Boon, L., van der Vlag, J., Heise, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3376 · Cited by 272 · see citing works
Immune Response and the Tumor Microenvironment: How They Communicate to Regulate Gastric Cancer
Lee, K., Hwang, H. K., & Nam, K. T. (2014) · Gut and Liver · doi:10.5009/gnl.2014.8.2.131 · Cited by 162 · see citing works
Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia
Seki, M., Kimura, S., Isobe, T., Yoshida, K., Ueno, H., Nakajima-Takagi, Y., Wang, C., Lin, L., Kon, A., Suzuki, H., et al. (2017) · Nature Genetics · doi:10.1038/ng.3900 · Cited by 138 · see citing works
Updates on esophageal and gastric cancers
Gallo, A. E. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i20.3237 · Cited by 127 · see citing works
Zhuang, Y., Peng, L., Zhao, Y., Shi, Y., Mao, X., Guo, G., Chen, W., Liu, X., Zhang, J., Liu, T., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1241-5 · Cited by 127 · see citing works
Self-citationHosokawa, H., Ungerbäck, J., Wang, X., Matsumoto, M., Nakayama, K. I., Cohen, S. M., Tanaka, T., & Rothenberg, E. V. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.024 · Cited by 116 · see citing works
Oikawa, T., Yamada, T., Kihara-Negishi, F., Yamamoto, H., Kondoh, N., Hitomi, Y., & Hashimoto, Y. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400534 · Cited by 109 · see citing works
The Transcription Factor PU.1 is a Critical Regulator of Cellular Communication in the Immune System
Turkistany, S. A., & DeKoter, R. P. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0147-9 · Cited by 96 · see citing works
Cai, W., Dong, Z.-N., Fu, X.-T., Lin, L., Wang, L., Ye, G.-D., Luo, Q., & Chen, Y. (2020) · Theranostics · doi:10.7150/thno.47938 · Cited by 89 · see citing works
The role of dendritic cells in cancer
Hansen, M., & Andersen, M. H. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0592-y · Cited by 85 · see citing works
Tao, L., Wang, X., & Zhou, Q. (2019) · Cell Biology International · doi:10.1002/cbin.11272 · Cited by 74 · see citing works
Kashimura, S., Saze, Z., Terashima, M., Soeta, N., Ohtani, S., Osuka, F., Kogure, M., & Gotoh, M. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0090-9 · Cited by 68 · see citing works
Gao, N., & Ye, B. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110239 · Cited by 55 · see citing works
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells
Yuki, H., Ueno, S., Tatetsu, H., Niiro, H., Iino, T., Endo, S., Kawano, Y., Komohara, Y., Takeya, M., Hata, H., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431429 · Cited by 47 · see citing works
Angiogenesis-Related Gene Expression Signatures Predicting Prognosis in Gastric Cancer Patients
Ren, H., Zhu, J., Yu, H., Bazhin, A. V., Westphalen, C. B., Renz, B. W., Jacob, S., Lampert, C., Werner, J., Angele, M. K., et al. (2020) · Cancers · doi:10.3390/cancers12123685 · Cited by 40 · see citing works
Rimmelé, P., Komatsu, J., Hupé, P., Roulin, C., Barillot, E., Dutreix, M., Conseiller, E., Bensimon, A., Moreau-Gachelin, F., & Guillouf, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4691 · Cited by 38 · see citing works
Heterozygous deletion of the PU.1 locus in human AML
Bonadies, N., Pabst, T., & Mueller, B. U. (2010) · Blood · doi:10.1182/blood-2009-03-212225 · Cited by 33 · see citing works
Transcription factor PU.1 is involved in the progression of glioma
Xu, Y., Gu, S., Bi, Y., Qi, X., Yan, Y., & Lou, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.7766 · Cited by 33 · see citing works
PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity
Tschan, M. P., Reddy, V. A., Ress, A., Arvidsson, G., Fey, M. F., & Torbett, B. E. (2008) · Oncogene · doi:10.1038/sj.onc.1211004 · Cited by 31 · see citing works
Localization of the human oncogene SPI1 on chromosome 11, region p11.22
Cong, N. V., Ray-Gallet, D., Gross, M., de Tand, M.-F., Frézal, J., & Moreau-Gachelin, F. (1990) · Human Genetics · doi:10.1007/bf00210807 · Cited by 28 · see citing works
Yang, H., Liang, H., Yan, J.-S., Tao, R., Hao, S., & Ma, L. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1106-x · Cited by 26 · see citing works
The significance of low PU.1 expression in patients with acute promyelocytic leukemia
Zhu, X., Zhang, H., Qian, M., Zhao, X., Yang, W., Wang, P., Zhang, J., & Wang, K. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-22 · Cited by 21 · see citing works
PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
Ueno, S., Tatetsu, H., Hata, H., Iino, T., Niiro, H., Akashi, K., Tenen, D. G., Mitsuya, H., & Okuno, Y. (2009) · Oncogene · doi:10.1038/onc.2009.263 · Cited by 20 · see citing works
High expression of PU.1 is associated with Her‑2 and shorter survival in patients with breast cancer
Lin, J., Liu, W., Luan, T., Yuan, L., Jiang, W., Cai, H., Yuan, W., Wang, Y., Zhang, Q., & Wang, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.7204 · Cited by 20 · see citing works
Okugawa, Y., Mohri, Y., Tanaka, K., Kawamura, M., Saigusa, S., Toiyama, Y., Ohi, M., Inoue, Y., Miki, C., & Kusunoki, M. (2016) · Oncology Reports · doi:10.3892/or.2016.5054 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Meng, X., Cheng, Z.-L., Lu, Z., Tan, Y., Jia, X., & Zhang, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978851 · Cited by 39 · see citing works
Zhao, F. Q., Tian, H., Wang, Y., Zhang, J., Liu, F., & Fu, L. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03364-5 · Cited by 38 · see citing works
Wu, Z. K., Bai, X., Lu, Z., Liu, S., & Jiang, H. (2022) · Journal of Immunology Research · doi:10.1155/2022/6450721 · Cited by 36 · see citing works
Jiang, Y., Zhao, J., Liu, Y., Hu, J., Gao, L., Hui, W., & Cui, D. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05149-1 · Cited by 33 · see citing works
Feng, H., Wang, T., Ye, J., Yang, Y., Huang, X., Lai, D., Lv, Z., Huang, Y., & Zhang, X. (2022) · Discover Oncology · doi:10.1007/s12672-022-00592-0 · Cited by 20 · see citing works
Zheng, P., Tan, Y., Liu, Q., Wu, C.-W., Kang, J., Liang, S., Zhu, L.-M., Yan, K., Zeng, L., & Chen, B.-L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26993 · Cited by 18 · see citing works
Hou, G., Zuo, H., Shi, J. F., Dai, D., Wang, H., Song, X., Guo, X., & Tao, G. (2023) · PubMed Central · Cited by 15 · see citing works
Qiu, P., Li, X., Gong, M., Wen, P., Wen, J., Xu, L., & Wang, G. (2023) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2023/2021515 · Cited by 13 · see citing works
Yang, J., Liu, C., Guan, J., Wang, Y., Su, J., Wang, Y., & Liu, S. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109425 · Cited by 12 · see citing works
Huang, J., Chen, M., Pei, W., Xu, Z., Ning, J., & Chen, C. (2022) · Journal of Cancer · doi:10.7150/jca.79640 · Cited by 12 · see citing works
Self-citationLiu, C., Qiu, X., Gao, J., Gong, Z., Zhou, X., Luo, H., & Geng, X. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17844 · Cited by 11 · see citing works
Song, Q., Wang, Y., & Liu, S. (2024) · Cancer Innovation · doi:10.1002/cai2.138 · Cited by 7 · see citing works
Cai, X., Hong, L., Liu, Y., Huang, X., Lai, H., & Shao, L. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2137421 · Cited by 6 · see citing works
Feng, X., Zheng, J., Peng, S., Jiang, A., Ng, K., Lyu, C., Jin, Q., & Chen, L. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1242 · Cited by 6 · see citing works
Multi-omics joint screening of biomarkers related to M2 macrophages in gastric cancer
Wang, X., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01623-8 · Cited by 5 · see citing works
Chen, X., Dong, T., Yang, L., Jin, L., Lin, W., Zhang, F., Han, Y., & Huang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.904304 · Cited by 5 · see citing works
Comprehensive Analysis of Stromal and Serum Markers in Gastric Cancer
Kovaleva, O. V., Алексеевна, П. П., Chang, V. L., Ognerubov, N. A., Gratchev, A. N., Козлов, Н. А., Stilidi, I. S., & Kushlinskii, N. E. (2023) · Acta Naturae · doi:10.32607/actanaturae.11753 · Cited by 5 · see citing works
Zhao, Y., Xiang, Q.-M., Chen, J.-L., Zhang, L., Zheng, W.-L., Ke, D., Shi, R.-S., & Yang, K.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990247 · Cited by 4 · see citing works
Li, Z., Wu, H., Wei, C., Jia, Y., Zhao, W., Feng, X., Bian, F., Zhang, P., Liao, Q., Pan, Z., et al. (2025) · 3 Biotech · doi:10.1007/s13205-025-04452-w · Cited by 3 · see citing works
Aravind, A., Mathew, R. T., Kuruba, L., Vijayakumar, M., & Prasad, T. S. K. (2024) · Molecular Omics · doi:10.1039/d4mo00112e · Cited by 3 · see citing works
A prognostic model for gastric cancer constructed by multiple machine learning algorithms
Yang, X., Huang, X., Ying, W., Deng, T., Zhang, J., & Ding, Q. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10629-7 · Cited by 3 · see citing works
Huang, Y., Zou, Y., Tian, Y., Yang, Z., Hou, Z., Li, P., Liu, F., Ling, J., & Wen, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009881 · Cited by 3 · see citing works
Zhao, L., Teng, Q., Liu, Y., Chen, H., Chong, W., Du, F., Xiao, K., Sang, Y., Ma, C., Cui, J., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1017767 · Cited by 3 · see citing works
Chen, L., Chen, H., Chen, Z., Zhang, K., Zhang, H., Xu, J., & Chen, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-12046-y · Cited by 2 · see citing works
Tiwari, A. K., Jain, D., Tiwari, J. K., Kishore, S., Singh, A. K., Shrivastava, S. K., & Khattri, A. (2025) · Oral Oncology Reports · doi:10.1016/j.oor.2025.100735 · Cited by 1 · see citing works
Gile, J. J., Mondello, P., Wang, Z., Li, Y., Bansal, R., Gandhi, S., Zhang, H., Babadi, E., Martinez, K., McCoy, G., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00623-w · Cited by 1 · see citing works
Xue, Z., Peng, Q., Liu, Z. G., & Sun, S. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0321 · Cited by 1 · see citing works
Liu, Z., Qin, Z., Li, H., Zhu, L., He, L., Chen, N., Zhu, D., Liu, Q., Dai, L., & Peng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02669-6 · Cited by 1 · see citing works
Zhou, J.-W., Zhang, Y., Huang, Z.-Y., Yuan, Y., & Jin, J. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.1947 · Cited by 1 · see citing works
Zhang, F., Zhou, C., Wang, X., Liu, Y., Hou, Y., & Niu, L. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155920 · Cited by 1 · see citing works
Wang, Y., Li, X., Lv, X., Zhang, P., & Liu, H. (2026) · Inflammation · doi:10.1007/s10753-025-02363-9
“Notably, the transcription factor SPI1—essential for the differentiation and function of lymphoid and myeloid cells [25 ]—has also been implicated in inflammatory regu - lation.”
Jiang, L., Bin, Y., Huang, Y., Wu, L., Qiu, X., Du, Y., Mi, J., Liu, K., Deng, Y., Ning, J., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101374
Xiaodong, S., Yao, S., Cao, K., Cai, X., Tianshi, S., & Chen, K. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4857096
Gile, J. J., Mondello, P., Wang, Z., Li, Y., Bansal, R., Gandhi, S., Zhang, H., Babadi, E., Martinez, K., McCoy, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4889200/v1
Shao, X., Yao, S., Dai, J., Cao, K., Cai, X., Song, T., & Chen, K. (2025) · Research Square · doi:10.21203/rs.3.rs-6097394/v1
Shao, X., Yao, S., Dai, J., Cao, K., Cai, X., Song, T., & Chen, K. (2025) · Research Square · doi:10.21203/rs.3.rs-6097394/v2
Anderson, A. N., Queitsch, K., Giske, N. R., Jones, J. A., Pang, A., Zucker, A., Huang, G., Rounds, C. C., Smith, B. J., Swain, J. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.12.717781
Li, D. C., Tuo, Y., Sai, L., Xu, X., Peng, F., Yan, Z., Yang, Q., Zhao, H., & Zhang, R. (2026) · Biomolecules · doi:10.3390/biom16050675
Ramani, M., Nguyen, N., Solis, J., Tenen, D. G., & Trinh, B. Q. (2026) · Biology · doi:10.3390/biology15181657
- Authors
- Huang, J., Chen, W., Jie, Z., & Jiang, M.
- Affiliations
- First Affiliated Hospital of Nanchang University (CN)
- Corresponding author
- Jie, Zhigang
- Jiang, Mengmeng
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-14
- Volume
- 12
- Pages
- 820568-820568
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC8882873
- OpenAlex
- W4213006142
- Cited by
- 38
- References
- 45
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 7 · 2023: 5 · 2022: 11
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81960503, YC2020-B054)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
- Keywords
- PU.1, gastric cancer, tumor immune infiltration, prognostic signature, risk prediction nomogram, tumor-infiltrating immune cells, M2 macrophages, natural killer cells, cell cycle regulation, immunotherapy targets, diploidy, DNA methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
